Skip to main content

All Access Subscription

Get unlimited access to our full publication and article library.

Get Access Now

Interested in Group Sales? Learn more

Teriflunomide, an orally administered inhibitor of dihydro-orotate dehydrogenase, was found to be superior to placebo in reducing relapses in a 2-year, Phase 3 clinical trial in patients with multiple sclerosis.

Teriflunomide: A New Oral Agent for the Treatment of Multiple Sclerosis